Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067609774> ?p ?o ?g. }
- W2067609774 endingPage "1381" @default.
- W2067609774 startingPage "1369" @default.
- W2067609774 abstract "Signaling of the receptor for advanced glycation end products (RAGE) has been implicated in the development of injury-elicited vascular complications. Soluble RAGE (sRAGE) acts as a decoy of RAGE and has been used to treat pathological vascular conditions in animal models. However, previous studies used a high dose of sRAGE produced in insect Sf9 cells (sRAGE(Sf9))and multiple injections to achieve the therapeutic outcome. Here, we explore whether modulation of sRAGE N-glycoform impacts its bioactivity and augments its therapeutic efficacy. We first profiled carbohydrate components of sRAGE produced in Chinese hamster Ovary cells (sRAGE(CHO)) to show that a majority of its N-glycans belong to sialylated complex types that are not shared by sRAGE(Sf9). In cell-based NF-κB activation and vascular smooth muscle cell (VSMC) migration assays, sRAGE(CHO) exhibited a significantly higher bioactivity relative to sRAGE(Sf9) to inhibit RAGE alarmin ligand-induced NF-κB activation and VSMC migration. We next studied whether this N-glycoform-associated bioactivity of sRAGE(CHO) is translated to higher in vivo therapeutic efficacy in a rat carotid artery balloon injury model. Consistent with the observed higher bioactivity in cell assays, sRAGE(CHO) significantly reduced injury-induced neointimal growth and the expression of inflammatory markers in injured vasculature. Specifically, a single dose of 3 ng/g of sRAGE(CHO) reduced neointimal hyperplasia by over 70%, whereas the same dose of sRAGE(Sf9) showed no effect. The administered sRAGE(CHO) is rapidly and specifically recruited to the injured arterial locus, suggesting that early intervention of arterial injury with sRAGE(CHO) may offset an inflammatory circuit and reduce the ensuing tissue remodeling. Our findings showed that the N-glycoform of sRAGE is the key determinant underlying its bioactivity and thus is an important glycobioengineering target to develop a highly potent therapeutic sRAGE for future clinical applications.The specific N-glycoform modification is the key underlying sRAGE bioactivity Markedly reduced sRAGE dose to attenuate neointimal hyperplasia and inflammation Provide a molecular target for glycobioengineering of sRAGE as a therapeutic protein Blocking RAGE alarmin ligands during acute injury phase offsets neointimal growth." @default.
- W2067609774 created "2016-06-24" @default.
- W2067609774 creator A5003469282 @default.
- W2067609774 creator A5008927356 @default.
- W2067609774 creator A5016031452 @default.
- W2067609774 creator A5017322165 @default.
- W2067609774 creator A5024215680 @default.
- W2067609774 creator A5027495200 @default.
- W2067609774 creator A5028607531 @default.
- W2067609774 creator A5029696367 @default.
- W2067609774 creator A5029786186 @default.
- W2067609774 creator A5033582636 @default.
- W2067609774 creator A5036807553 @default.
- W2067609774 creator A5038242144 @default.
- W2067609774 creator A5052816975 @default.
- W2067609774 creator A5060742163 @default.
- W2067609774 creator A5063406135 @default.
- W2067609774 creator A5074138515 @default.
- W2067609774 creator A5074784454 @default.
- W2067609774 creator A5078101542 @default.
- W2067609774 creator A5088697882 @default.
- W2067609774 date "2013-10-17" @default.
- W2067609774 modified "2023-10-16" @default.
- W2067609774 title "The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth" @default.
- W2067609774 cites W1492834548 @default.
- W2067609774 cites W1503258737 @default.
- W2067609774 cites W1528046172 @default.
- W2067609774 cites W1594856996 @default.
- W2067609774 cites W1946370590 @default.
- W2067609774 cites W1967874738 @default.
- W2067609774 cites W1969243162 @default.
- W2067609774 cites W1972816014 @default.
- W2067609774 cites W1984830754 @default.
- W2067609774 cites W1991338634 @default.
- W2067609774 cites W1994251377 @default.
- W2067609774 cites W1997984454 @default.
- W2067609774 cites W2007395134 @default.
- W2067609774 cites W2021346724 @default.
- W2067609774 cites W2022660459 @default.
- W2067609774 cites W2026411958 @default.
- W2067609774 cites W2027604422 @default.
- W2067609774 cites W2040324519 @default.
- W2067609774 cites W2054435322 @default.
- W2067609774 cites W2055278845 @default.
- W2067609774 cites W2059217150 @default.
- W2067609774 cites W2062389480 @default.
- W2067609774 cites W2062729839 @default.
- W2067609774 cites W2073714833 @default.
- W2067609774 cites W2074901593 @default.
- W2067609774 cites W2083419397 @default.
- W2067609774 cites W2091499641 @default.
- W2067609774 cites W2094647922 @default.
- W2067609774 cites W2107565203 @default.
- W2067609774 cites W2111463022 @default.
- W2067609774 cites W2114688115 @default.
- W2067609774 cites W2116823777 @default.
- W2067609774 cites W2126658477 @default.
- W2067609774 cites W2128426645 @default.
- W2067609774 cites W2140504464 @default.
- W2067609774 cites W2146666237 @default.
- W2067609774 cites W2150594596 @default.
- W2067609774 cites W2161551178 @default.
- W2067609774 cites W2166511358 @default.
- W2067609774 cites W4241103062 @default.
- W2067609774 cites W43672043 @default.
- W2067609774 doi "https://doi.org/10.1007/s00109-013-1091-4" @default.
- W2067609774 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3846495" @default.
- W2067609774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24132651" @default.
- W2067609774 hasPublicationYear "2013" @default.
- W2067609774 type Work @default.
- W2067609774 sameAs 2067609774 @default.
- W2067609774 citedByCount "18" @default.
- W2067609774 countsByYear W20676097742013 @default.
- W2067609774 countsByYear W20676097742014 @default.
- W2067609774 countsByYear W20676097742015 @default.
- W2067609774 countsByYear W20676097742016 @default.
- W2067609774 countsByYear W20676097742018 @default.
- W2067609774 countsByYear W20676097742019 @default.
- W2067609774 countsByYear W20676097742020 @default.
- W2067609774 countsByYear W20676097742021 @default.
- W2067609774 countsByYear W20676097742022 @default.
- W2067609774 crossrefType "journal-article" @default.
- W2067609774 hasAuthorship W2067609774A5003469282 @default.
- W2067609774 hasAuthorship W2067609774A5008927356 @default.
- W2067609774 hasAuthorship W2067609774A5016031452 @default.
- W2067609774 hasAuthorship W2067609774A5017322165 @default.
- W2067609774 hasAuthorship W2067609774A5024215680 @default.
- W2067609774 hasAuthorship W2067609774A5027495200 @default.
- W2067609774 hasAuthorship W2067609774A5028607531 @default.
- W2067609774 hasAuthorship W2067609774A5029696367 @default.
- W2067609774 hasAuthorship W2067609774A5029786186 @default.
- W2067609774 hasAuthorship W2067609774A5033582636 @default.
- W2067609774 hasAuthorship W2067609774A5036807553 @default.
- W2067609774 hasAuthorship W2067609774A5038242144 @default.
- W2067609774 hasAuthorship W2067609774A5052816975 @default.
- W2067609774 hasAuthorship W2067609774A5060742163 @default.
- W2067609774 hasAuthorship W2067609774A5063406135 @default.
- W2067609774 hasAuthorship W2067609774A5074138515 @default.